The Roles of EXO1 and RPA1 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Figure 1

The RPA1 rs5030740, EXO1 rs1776148, and rs1047840 polymorphisms are significantly associated with prognosis of lung cancer treated with platinum-based chemotherapy. (a) The RPA1 rs5030740 is significantly associated with PFS in lung cancer patients treated with platinum-based chemotherapy in recessive model. (b) The EXO1 rs1776148 is significantly associated with OS in lung cancer patients treated with platinum-based chemotherapy in additive model. (c) The EXO1 rs1776148 is significantly associated with OS in lung cancer patients treated with platinum-based chemotherapy in dominant model. (d) The EXO1 rs1047840 is significantly associated with OS in lung cancer patients treated with platinum-based chemotherapy in recessive model.

(a)

(b)

(c)

(d)